Vantage logo

Intellia proves its point

The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.

Vantage logo

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?